PRESS RELEASE : Biotest AG: Annual General Meeting approves dividend distribution

DGAP-News: Biotest AG / Key word(s): AGM/EGM 
Biotest AG: Annual General Meeting approves dividend distribution 
2021-05-11 / 14:30 
The issuer is solely responsible for the content of this announcement. 
=---------------------------------------------------------------------------------------------------------------------- 
PRESS RELEASE 
Biotest AG: Annual General Meeting approves dividend distribution 
- Distribution of EUR 0.04 per preferred share 
- Broad majority on all agenda items 
Dreieich 11 May 2021. At the second ordinary, virtual Annual General Meeting on 11 May 2021, the shareholders of 
Biotest AG resolved to distribute a dividend. A total of 47.75 % of the share capital was represented. The resolution 
on the appropriation of the net profit was passed with 99.96% approval for a distribution of EUR 0.04 per preference 
share. A total amount of about EUR 0.8 million will thus be distributed. 
The shareholders approved the actions of the members of the Executive Board and the Supervisory Board for the 2020 
financial year by a large majority and confirmed all other items on the agenda with a large majority of votes in 
favour. 
The speech of Dr. Michael Ramroth, CEO of Biotest AG, and Dr. Georg Floß, COO of Biotest AG at the Annual General 
Meeting is available at: 
https://www.biotest.com/de/en/investor_relations/shareholders_meeting_2021.cfm 
About Biotest 
Biotest is a provider of plasma proteins and biological drugs. With a value added chain that extends from pre-clinical 
and clinical development to worldwide sales, Biotest has specialised primarily in the areas of clinical immunology, 
haematology and intensive medicine. Biotest develops and markets immunoglobulins, coagulation factors and albumin based 
on human blood plasma. These are used for diseases of the immune and haematopoietic systems. Biotest has more than 
1,900 employees worldwide. The ordinary and preference shares of Biotest AG are listed in the Prime Standard on the 
German stock exchange. 
IR contact 
Dr Monika Buttkereit 
Phone: [phone] 
Mail: [e-mail] 
PR contact 
Dirk Neumüller 
Phone: [phone] 
Mail: [e-mail] 
Biotest AG, Landsteinerstr. 5, 63303 Dreieich, Germany, www.biotest.com 
Ordinary shares: securities' ID No. 522720; ISIN DE0005227201 
Preference shares: securities' ID No. 522723; ISIN DE0005227235 
Listing: Frankfurt (Prime Standard) 
Open Market: Berlin, Düsseldorf, Hamburg/ Hanover, Munich, Stuttgart, Tradegate 
Disclaimer 
This document contains forward-looking statements on overall economic development as well as on the business, earnings, 
financial and assets position of Biotest AG and its subsidiaries. These statements are based on current plans, 
estimates, forecasts and expectations of the company and are thus subject to risks and elements of uncertainty that 
could result in significant deviation of actual developments from expected developments. The forward-looking statements 
are only valid at the time of publication. Biotest does not intend to update the forward-looking statements and assumes 
no obligation to do so. 
=---------------------------------------------------------------------------------------------------------------------- 
2021-05-11 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. 
The issuer is solely responsible for the content of this announcement. 
The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. 
Archive at www.dgap.de 
=---------------------------------------------------------------------------------------------------------------------- 
Language:     English 
Company:      Biotest AG 
              Landsteinerstraße 5 
              63303 Dreieich 
              Germany 
Phone:        0 61 03 - 8 01-0 
Fax:          0 61 03 - 8 01-150 
E-mail:       [e-mail] 
Internet:     http://www.biotest.de 
ISIN:         DE0005227235, DE0005227201 
WKN:          522723, 522720 
Listed:       Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, 
              Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange 
EQS News ID:  1195273 
 
End of News   DGAP News Service 
=------------ 

1195273 2021-05-11

 
Image link: 
https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1195273&application_name=news

(END) Dow Jones Newswires

May 11, 2021 08:30 ET (12:30 GMT)